Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
| Brand name | IRBESARTAN AND HYDROCHLOROTHIAZIDE |
| Generic name | IRBESARTAN AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, IRBESARTAN |
| Distributed by / for | Solco Healthcare US, LLC Cranbury, NJ 08512 |
| NDC | 43547-330-03 |
| Full product label | Irbesartan and Hydrochlorothiazide Tablets, USP 150/12.5 mg Rx 30 Tablets Only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xunqiao, Linhai, Zheijang 317024, China Distributed by: Solco Healthcare US, LLC Cranbury, NJ 08512 NDC 43547-330-03 |
| Recalling firm | Prinston Pharmaceutical Inc |
| Distribution | Nationwide |
| Quantity | 87505 bottles |
| Recall initiated | 2019-01-18 |
| Report date | 2019-02-06 |
| Recall completed | — |
| Recall number | D-0413-2019 |
| Classification | Class II |
| FDA status | Completed |
| Origin on file | Somerset NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗